Table 2.
Summary of measures of quality of care for cardiovascular risk factors in study populations with serious mental illness (SMI), United States 2000–2013
| PANEL 1: ADHERENCE TO GUIDELINES FOR CARE AND TREATMENT OF DIABETES MELLITUS | |||||
|---|---|---|---|---|---|
| Measure | Studies (N) | Measures Abstracted (N) | Measure range in sample with SMI | Guideline Adherence in Study Samples with and without SMI (N Measures) | Studies Reviewed |
| Percent of Patients Receiving: | |||||
| Overall guideline-based care | 2 | 6 | 19% – 56% | More likely in SMI sample: 1 Less likely in SMI sample: 1 No difference: 1 |
(Goldberg et al., 2007b; Leung et al., 2011) |
| Diabetic eye examinations | 8 | 20 | 30% – 83% | More likely in SMI sample: 1 Less likely in SMI sample: 3 No difference: 10 |
(Banta et al., 2009; Clark et al., 2009; Frayne et al., 2005; Goldberg et al., 2007b; Green et al., 2010; Kilbourne et al., 2011; Kilbourne et al., 2008; Leung et al., 2011) |
| Diabetic foot examinations | 3 | 5 | 78% – 87% | More likely in SMI sample: 0 Less likely in SMI sample: 2 No difference: 1 |
(Goldberg et al., 2007b; Kilbourne et al., 2011; Kilbourne et al., 2008) |
| Glycosated hemoglobin (HBA1c) testing | 7 | 20 | 43% – 89% | More likely in SMI sample: 0 Less likely in SMI sample: 2 No difference: 9 |
(Banta et al., 2009; Clark et al., 2009; Frayne et al., 2005; Goldberg et al., 2007b; Green et al., 2010; Krein SL et al., 2006; Leung et al., 2011) |
| Diabetic nephropathy testing | 5 | 13 | 50% – 79% | More likely in SMI sample: 2 Less likely in SMI sample: 2 No difference: 6 |
(Clark et al., 2009; Goldberg et al., 2007b; Green et al., 2010; Kilbourne et al., 2008; Leung et al., 2011) |
| Pharmacologic diabetes mellitus treatment | 2 | 3 | 70% – 95% | More likely in SMI sample: 0 Less likely in SMI sample: 0 No difference: 1 |
(Nasrallah et al., 2006; Weiss et al., 2006) |
| PANEL 2: ADHERENCE TO GUIDELINES FOR CARE AND TREATMENT OF CO-MORBID CONDITIONS AMONG PERSONS WITH DIABETES MELLITUS | |||||
| Percent of Patients Receiving: | |||||
| Lipid testing | 9 | 30 | 26 – 77% | More likely in SMI sample: 1 Less likely in SMI sample: 4 No difference: 10 |
(Banta et al., 2009; Clark et al., 2009; Frayne et al., 2005; Goldberg et al., 2007b; Green et al., 2010; Krein SL et al., 2006; Leung et al., 2011) |
| Pharmacologic dyslipidemia treatment | 2 | 5 | 52% – 67% | More likely in SMI sample: 0 Less likely in SMI sample: 1 No difference: 1 |
(Kreyenbuhl et al., 2008; Weiss et al., 2006) |
| Pharmacologic hypertension treatment | 1 | 2 | 84% | More likely in SMI sample: 0 Less likely in SMI sample: 0 No difference: 1 |
(Weiss et al., 2006) |
| Angiotensin Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers | 2 | 3 | 48% – 69% | More likely in SMI sample: 0 Less likely in SMI sample: 0 No difference: 1 |
(Kreyenbuhl et al., 2008; Weiss et al., 2006) |
| Aspirin | 1 | 2 | 36% | More likely in SMI sample: 0 Less likely in SMI sample: 0 No difference: 1 |
(Weiss et al., 2006) |
| PANEL 3: ADHERENCE TO GUIDELINES FOR CARE AND TREATMENT OF DYSLIPIDEMIA | |||||
| Percent of Patients Receiving: | |||||
| Pharmacologic dyslipidemia treatment | 2 | 2 | 12% – 67% | More likely in SMI sample: 0 Less likely in SMI sample: 0 No difference: 0 |
(Kreyenbuhl et al., 2008; Nasrallah et al., 2006) |